Biotec Pharmacon’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucans AS has extended the distribution agreement for Woulgan in Germany with Rogg Verbandstoffe (Rogg) for an additional 12 months with automatic renewal thereafter
Svein Lien, CEO of Biotec Pharmacon ASA says: -We are very pleased to extend this agreement, providing our customers with a consistent presence in the German market. Rogg will continue to promote the benefits of Woulgan to customers in physician offices and pharmacies and Biotec will support Rogg, by creating customer demand for Woulgan through its marketing division. Sales to the physician and pharmacies channel are growing and both parties are encouraged for the future collaboration in the German market.
Woulgan® is a premium priced product targeting stalled wounds in the professional wound care market. Clinical experience with Woulgan® demonstrates significantly improved healing compared to standard care which drives repeated customer selection.
Rogg is a German company founded in 1970 and is one of Germany’s leading suppliers of wound care products to the health sector. The company is primarily supplying physician offices and pharmacies, which are important segments for Woulgan®. Rogg is owned and run by Prof. Dr. Dr Ulrich Hemel, who has a long track record managing wound care companies.